Cargando…
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to exa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306017/ https://www.ncbi.nlm.nih.gov/pubmed/34300079 http://dx.doi.org/10.3390/ijerph18147629 |
_version_ | 1783727709007904768 |
---|---|
author | Kasprzak, Annika Kaivers, Jennifer Nachtkamp, Kathrin Haas, Rainer Kobbe, Guido Gattermann, Norbert Germing, Ulrich |
author_facet | Kasprzak, Annika Kaivers, Jennifer Nachtkamp, Kathrin Haas, Rainer Kobbe, Guido Gattermann, Norbert Germing, Ulrich |
author_sort | Kasprzak, Annika |
collection | PubMed |
description | The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS. |
format | Online Article Text |
id | pubmed-8306017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83060172021-07-25 Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? Kasprzak, Annika Kaivers, Jennifer Nachtkamp, Kathrin Haas, Rainer Kobbe, Guido Gattermann, Norbert Germing, Ulrich Int J Environ Res Public Health Review The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS. MDPI 2021-07-18 /pmc/articles/PMC8306017/ /pubmed/34300079 http://dx.doi.org/10.3390/ijerph18147629 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kasprzak, Annika Kaivers, Jennifer Nachtkamp, Kathrin Haas, Rainer Kobbe, Guido Gattermann, Norbert Germing, Ulrich Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title | Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title_full | Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title_fullStr | Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title_full_unstemmed | Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title_short | Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? |
title_sort | guidelines for myelodysplastic syndromes: converting evidence into action? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306017/ https://www.ncbi.nlm.nih.gov/pubmed/34300079 http://dx.doi.org/10.3390/ijerph18147629 |
work_keys_str_mv | AT kasprzakannika guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT kaiversjennifer guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT nachtkampkathrin guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT haasrainer guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT kobbeguido guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT gattermannnorbert guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction AT germingulrich guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction |